ARTICLE | Company News

Breakthrough designation for Global Blood's sickle cell therapy

January 9, 2018 7:27 PM UTC

Global Blood Therapeutics Inc. (NASDAQ:GBT) was up $7.55 (19%) to $47.15 on Tuesday after it said FDA granted voxelotor (formerly GBT440) breakthrough therapy designation to treat sickle cell disease.

Voxelotor is in the Phase III HOPE study to treat sickle cell patients ages 12 and older. Top-line data are expected this half from the dose-finding Part A of HOPE and in 1H19 from the dose-expansion Part B. The compound is also in the Phase IIa HOPE-KIDS 1 trial to treat patients ages six to 17. Global Blood reported interim data from HOPE-KIDS 1 in December but declined to provide a timeline for full results...

BCIQ Company Profiles

Global Blood Therapeutics Inc.